FLT3-ITD, RUNX1, ASXl1 and TP53 mutations, or a monosomal karyotype have been classified as AML with adverse risk, while NPM1 or biallelic CEBPA mutations are classified as favorable risk, based on treatment with standard induction chemotherapy [4]. This evidence concerns the gene TP53 and acute myeloid leukemia.